ArticleWorld journal of clinical oncology2025
Molecular mechanisms of thymopoietin in papillary thyroid cancer: Multiplatform gene expression data, gene knockout screening, and in-house immunohistochemistry.
Article in World journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nuclear envelope proteins in cancer: revisiting the significance of LEM-domain proteins.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough thymopoietin (TMPO) has been elucidated to be overexpressed in cancers, its underlying mechanisms are not yet fully understood.
aimTo investigate the expression and clinical significance of TMPO in papillary thyroid carcinoma (PTC).
methodsDatabases such as Gene Expression Omnibus, The Cancer Genome Atlas Program-Genotype-Tissue Expression, The Human Protein Atlas (THPA), and tissue microarrays were screened. Immunohistochemical staining scores and standardized mean difference were used to calculate expression levels, and summary receiver operating characteristic curves were plotted to evaluate diagnostic performance. A Gene Set Enrichment Analysis enrichment analysis was conducted to identify TMPO-related signaling pathways. A protein interaction network was constructed to identify hub genes. The impact of TMPO on PTC cell proliferation and the effects of its knockout were analyzed using clustered regularly interspaced short palindromic repeats (CRISPR) knockout screening and the Cancer Cell Line Encyclopedia database.
resultsThe TMPO protein was significantly overexpressed in PTC tissues, primarily localized in the cytoplasm and nuclear membrane. The mRNA level analysis showed mild overexpression of TMPO in PTC tissues, with a certain discriminatory value (area under the curve = 0.66). TMPO may promote cancer through involvement in cell adhesion, focal adhesion, leukocyte migration, and multiple cancer-related signaling pathways. Additionally,
conclusionTMPO is overexpressed in PTC and may serve as a therapeutic target and molecular biomarker for PTC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.